Incyte Announces Results from SCRATCH-AD Trial Demonstrating

– Adult patients with atopic dermatitis treated with Opzelura experienced rapid and substantial improvement in itch, which was sustained through Day 28

... | May 1, 2023

Related Keywords

United States , Washington , Delaware , Ohio , Jim Lee , Robert Bissonnette , Innovaderm Research , Exchange Commission , Group Vice , Us Census Bureau , Us Food Drug Administration , Incyte Corporation , Revolutionizing Atopic Dermatitis , Group Vice President , Global Assessment , Chief Executive Officer , Medical Director , Investigator Global Assessment , Drug Administration , Mississippi River , Full Prescribing Information , Boxed Warning , Medication Guide , Allergy Asthma , Incyte Corporation Stock Exchange , News , Information , Press Release , Adult , Patients , Ith , Topic , Dermatitis , Reated , Opzelura , Xperienced , Rapid , End , Ubstantial , Improvement , N , Which , Gas , Sustained , Through , Ay Incy Us45337c1027 ,